Clinical Trial Update: Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial (SiARa Cancer Study) evaluating Sintilimab for locally advanced, metastatic, or recurrent angiosarcoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angiosarcoma

Drugs mentioned

• Sintilimab (Tyvyt) (sintilimab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Locally Advanced Angiosarcoma, Metastatic Angiosarcoma | Phase 2 | Status: TERMINATED